

CITATION REPORT

List of articles citing

Discovering drugs to treat coronavirus disease 2019 (COVID-

DOI: 10.5582/ddt.2020.01012

Drug Discoveries and Therapeutics, 2020, 14, 58-60.

Source: <https://exaly.com/paper-pdf/76925568/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
961	Anti-tuberculosis (TB) chemotherapy dynamically rescues Th1 and CD8+ T effector levels in Han Chinese pulmonary TB patients. 2020 , 22, 119-126		5
960	Subcutaneous injection of IFN alpha-2b for COVID-19: an observational study. 2020 , 20, 723		21
959	Covid-19 Demographics from a Tertiary Care Center: Does It Depreciate Quality-of-Life?. 2020 , 1-8		4
958	2019-nCoV: a worldwide concern and facts. 2020 , 31, 1-8		2
957	Declaraci3n consenso de la Asociaci3n Colombiana de Medicina Cr3tica y Cuidados Intensivos (AMCI) para atenci3n y manejo del paciente pedi3trico con sospecha o confirmaci3n de infecci3n severa por SARS-CoV-2. 2020 , 20, 113-127		0
956	Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment. 2020 , 6, e05278		15
955	COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. 2020 , 49, 763-773		13
954	SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies. 2020 , 13, 255-260		12
953	In Silico De Novo Curcuminoid Derivatives From the Compound Library of Natural Products Research Laboratories Inhibit COVID-19 3CLpro Activity. 2020 , 15, 1934578X2095326		4
952	A Narrative Literature Review of Global Pandemic Novel Coronavirus Disease 2019 (COVID-19): Epidemiology, Virology, Potential Drug Treatments Available. 2020 , 12,		2
951	Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-nCoV and SARS-CoV through covalent linkage. 2020 , 533, 467-473		34
950	COVID-19 associated complications and potential therapeutic targets. 2020 , 886, 173548		10
949	COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making. 2020 , 1874, 188412		3
948	An open-label, randomized trial of the combination of IFN-β plus TFF2 with standard care in the treatment of patients with moderate COVID-19. 2020 , 27, 100547		17
947	A review of medications used to control and improve the signs and symptoms of COVID-19 patients. 2020 , 887, 173568		2
946	A review on coronavirus survivability on material's surfaces: present research scenarios, technologies and future directions. 2020 , 36, 1226-1239		7
945	Mesenchymal stem cell treatment in a critically ill COVID-19 patient: a case report. 2020 , 7, 17		11

944	Toxic metal exposure as a possible risk factor for COVID-19 and other respiratory infectious diseases. 2020 , 146, 111809	25
943	Virus database annotations assist in tracing information on patients infected with emerging pathogens. 2020 , 21, 100442	1
942	Síndrome inflamatorio multisistémico en niños con COVID-19: una visión desde la reumatología. 2020 , 28, 289-289	
941	Potential of tilapia (<i>Oreochromis niloticus</i>) viscera bioactive peptides as antiviral for SARS-CoV-2 (COVID 19). 2020 , 584, 012004	4
940	CURRENT THERAPEUTIC OPTIONS FOR CORONAVIRUS DISEASE-2019 [A PHARMACOLOGICAL REVIEW. 2020 , 42-50	
939	Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review. 2020 , 75, 458-466	19
938	A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules. 2020 , 104, 104326	12
937	Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. 2021 , 73, e4073-e4081	150
936	Fungi for Human Health. 2020 ,	
935	Credible Protein Targets and Curative Strategies for COVID-19: a Review. 2020 , 2, 1-10	3
934	Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. 2020 , 117, 27381-27387	101
933	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. 2020 , 1-24	11
932	Imposed mutational meltdown as an antiviral strategy. 2020 , 74, 2549-2559	6
931	Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. 2020 , 11, 585888	7
930	Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease. 2020 , 13, 463-484	5
929	Awareness of Health Professionals on COVID-19 and Factors Affecting It Before and During Index Case in North Shoa Zone, Ethiopia, 2020. 2020 , 13, 2979-2988	2
928	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. 2020 , 225, 152008	39
927	Therapeutic strategy for severe COVID-19 pneumonia from clinical experience. 2020 , 18, 205873922096159	0

926	SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic Management. 2020 , 8,	3
925	A multimodal deep learning-based drug repurposing approach for treatment of COVID-19. 2021 , 25, 1717-1730	13
924	Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach. 2020 , 163, 1787-1797	34
923	The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. 2020 , 5, 219	26
922	[Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality]. 2020 , 155, 375-381	5
921	Developing a holistic contingency plan: Challenges and dilemmas for cancer patients during the COVID-19. 2020 , 9, 6082-6092	3
920	Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19. 2021 , 87, 3439-3450	14
919	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. 2020 , 74, 109721	63
918	Will the COVID-19 Pandemic Change National Security and Healthcare in the Spectrum of Cardiovascular Disease?. 2020 , 45, 100645	5
917	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. 2020 , 53, 100719	79
916	Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review. 2020 , 16, 595-605	31
915	Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis. 2020 , 17,	23
914	Trend Dynamics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission in 16 Cities of Hubei Province, China. 2020 , 12, 699-709	5
913	Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen. 2020 , 16, 617-629	24
912	Chinese Herbal Medicines During the Covid-19 Pandemic: A Role for Observational Studies. 2020 , 26, 544-546	1
911	Volatile molecules for COVID-19: A possible pharmacological strategy?. 2020 , 81, 950	9
910	Going by the numbers : Learning and modeling COVID-19 disease dynamics. 2020 , 138, 110140	11
909	Bioengineered Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation. 2020 , 6, 6540-6555	13

908	Accuracy of three-dimensional virtual simulation of the soft tissues of the face in OrtoGOnBlender for correction of class II dentofacial deformities: an uncontrolled experimental case-series study. 2021 , 25, 319-335	3
907	Research on Covid-19 from Biophysical Perspective. 2020 , 1-14	
906	An update on COVID-19: SARS-CoV-2 life cycle, immunopathology, and BCG vaccination. 2021 , 51, 650-658	6
905	Cordycepin: a bioactive metabolite of C and polyadenylation inhibitor with therapeutic potential against COVID-19. 2020 , 1-8	7
904	Molecular dynamics simulation perception study of the binding affinity performance for main protease of SARS-CoV-2. 2020 , 1-16	9
903	COVID-19 Pandemic: Oral Health Challenges and Recommendations. 2020 , 14, S165-S170	6
902	Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease. 2020 , 17, 190	37
901	The role of pharmaceutical nanotechnology in the time of COVID-19 pandemic. 2020 , 15, 1571-1582	5
900	Milestones in Personalized Medicine: From the Ancient Time to Nowadays-the Provocation of COVID-19. 2020 , 11, 569175	6
899	Levels of fear and uncertainty regarding the spread of coronavirus disease (COVID-19) among university students. 2021 , 57, 1356-1364	21
898	Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality. 2020 , 155, 375-381	1
897	In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2. 2020 , 25,	8
896	Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. 2020 , 7, 606393	17
895	Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infection. 2020 , 13, 608-614	7
894	Repurposing Nucleoside Analogs for Human Coronaviruses. 2020 , 65,	28
893	Synergy of melanin and vitamin-D may play a fundamental role in preventing SARS-CoV-2 infections and halt COVID-19 by inactivating furin protease. 2020 , 5, 21	2
892	COVID-19: Therapeutics and interventions currently under consideration. 2020 , 66, 101058	8
891	The COVID-19 pandemic: A community approach. 2020 , 34, e14059	7

890	COVID-19: The Immune Responses and Clinical Therapy Candidates. 2020 , 21,	16
889	COVID-19: A review of the proposed pharmacological treatments. 2020 , 886, 173451	54
888	Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist. 2020 , 83, 1738-1748	17
887	Criticality of physical/social distancing, handwashing, respiratory hygiene and face-masking during the COVID-19 pandemic and beyond. 2020 , 74, e13656	3
886	Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of or and in the Stimulation of. 2020 , 11, 1091	10
885	Potential strategies for combating COVID-19. 2020 , 165, 2419-2438	3
884	The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients. 2020 , 62, 59-64	13
883	OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath. 2020 , 884, 173381	9
882	A Review on Currently Available Potential Therapeutic Options for COVID-19. 2020 , 13, 443-467	11
881	An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. 2020 , 144, 111639	28
880	The Course of Mild and Moderate COVID-19 Infections-The Unexpected Long-Lasting Challenge. 2020 , 7, ofaa286	9
879	Global Efforts towards Potential Therapeutic Options for COVID-19. 2020 , 12,	
878	Potential repurposed SARS-CoV-2 (COVID-19) infection drugs.. 2020 , 10, 26895-26916	20
877	Therapeutic and vaccine strategies against SARS-CoV-2: past, present and future. 2020 , 15, 471-482	8
876	BCG Against SARS-CoV-2: Second Youth of an Old Age Vaccine?. 2020 , 11, 1050	7
875	COVID-19: A Multidisciplinary Review. 2020 , 8, 383	61
874	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. 2020 , 21,	27
873	In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19. 2020 , 124, 103936	74

872	COVID-19 and the Kidneys: An Update. 2020 , 7, 423	48
871	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. 2020 , 59, 1195-1216	18
870	In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. 2020 , 56, 106119	24
869	When the fourth water and digital revolution encountered COVID-19. 2020 , 744, 140980	30
868	Novel Coronavirus Pneumonia Treatment With Traditional Chinese Medicine: Response Philosophy in Another Culture. 2020 , 8, 385	2
867	Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials. 2020 , 10, e039730	18
866	Could herbal medicine (Soshihotang) be a new treatment option for COVID-19?: a narrative review. 2020 , 9, 100480	2
865	Coronavirus Disease-2019 (COVID-19): An Updated Review. 2020 , 70, 389-400	25
864	COVID-19, Mitochondria, and Interferon. 2020 , 40, 466-467	3
863	The COVID-19 Pandemic and Planetary Health. A Critical Review of Epidemiology, Prevention, Clinical Characteristics and Treatments for Oral, Head and Neck Health Professionals. Do We Have a Roadmap?. 2020 , 24, e351-e358	3
862	COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. 2020 , 180, 114184	32
861	The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19. 2020 , 258, 118185	55
860	The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report. 2020 , 144, 459-462	10
859	Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic. 2020 , 7, 444	53
858	An Examination on the Transmission of COVID-19 and the Effect of Response Strategies: A Comparative Analysis. 2020 , 17,	12
857	Potential diagnostics and therapeutic approaches in COVID-19. 2020 , 510, 488-497	25
856	Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. 2020 , 25, 1822-1838	5
855	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. 2020 , 10,	4

854	Cardiovascular manifestation and treatment in COVID-19. 2020 , 83, 704-709	16
853	A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019. 2020 , 99, e21402	2
852	Understanding COVID-19: From Origin to Potential Therapeutics. 2020 , 17,	8
851	Favipiravir use for SARS CoV-2 infection. 2020 , 72, 1542-1552	11
850	Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients. 2020 , 11, 582348	11
849	Ayurveda and Allopathic Therapeutic Strategies in Coronavirus Pandemic Treatment 2020. 2020 , 6, 1-10	10
848	COVID-19: An overview for dermatologists. 2020 , 59, 1437-1449	12
847	The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19). 2020 , 16, 933-946	4
846	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. 2020 , 11, 562264	5
845	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. 2020 , 19, 4291-4315	36
844	Stopping the COVID-19 Pandemic: A Review on the Advances of Diagnosis, Treatment, and Control Measures. 2020 , 2020, 9121429	10
843	Therapeutic modalities and novel approaches in regenerative medicine for COVID-19. 2020 , 56, 106208	15
842	A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. 2020 , 2, 1-13	26
841	Drug repurposing approach to fight COVID-19. 2020 , 72, 1479-1508	165
840	Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. 2020 , 11, 4417	195
839	Characteristics, laboratories, and prognosis of severe COVID-19 in the Tokyo metropolitan area: A retrospective case series. 2020 , 15, e0239644	10
838	Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease. 2020 , 46, 139	35
837	Phototherapy as a Rational Antioxidant Treatment Modality in COVID-19 Management; New Concept and Strategic Approach: Critical Review. 2020 , 9,	9

836	Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs. 2020 , 8, 497	10
835	Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review. 2020 , 7, 143	23
834	SARS-CoV-2 and rhinovirus/enterovirus co-infection in a critically ill young adult patient in Colombia. 2020 , 40, 34-43	3
833	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). 2020 , 63, 13205-13227	18
832	Depression and anxiety among university students during the COVID-19 pandemic in Bangladesh: A web-based cross-sectional survey. 2020 , 15, e0238162	215
831	Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel Method. 2020 , 25,	36
830	Slowing the Spread and Minimizing the Impact of COVID-19: Lessons from the Past and Recommendations for the Plastic Surgeon. 2020 , 146, 681-689	7
829	Is Nanotechnology Helping in the Fight Against COVID-19?. 2020 , 2,	19
828	Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking. 2020 , 20, 7311-7323	17
827	Coronavirus disease 2019 infection in patients with recent cardiac surgery: does chronic anticoagulant therapy have a protective effect?. 2020 , 21, 765-771	7
826	Smoking and COVID-19: Adding Fuel to the Flame. 2020 , 21,	31
825	Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines. 2020 , 11, 582025	11
824	What are the drugs having potential against COVID-19?. 2020 , 1-21	4
823	Cardiac Arrhythmias in Critically Ill Patients With COVID-19: A Brief Review. 2021 , 35, 3789-3796	6
822	Potential statin drug interactions in elderly patients: a review. 2020 , 16, 1133-1145	7
821	COVID-19 Pandemic: A Case for Phytomedicines. 2020 , 15, 1934578X20945086	14
820	COVID-19: EPIDEMIOLOGY, PATHOGENICITY AND GLOBAL UPDATES. 2020 , 16-28	
819	COVID-19 Pandemic: from Molecular Biology, Pathogenesis, Detection, and Treatment to Global Societal Impact. 2020 , 6, 1-16	21

818	COVID-19 Therapeutic Options Under Investigation. 2020 , 11, 1196	49
817	Natural products as home-based prophylactic and symptom management agents in the setting of COVID-19. 2020 , 34, 3148-3167	31
816	Favipiravir tautomerism: a theoretical insight. 2020 , 139, 145	9
815	Treatment Options for COVID-19: A Review. 2020 , 7, 480	46
814	Children in Coronaviruses' Wonderland: What Clinicians Need to Know. 2020 , 12, e2020042	6
813	Pharmacological treatments of COVID-19. 2020 , 72, 1446-1478	16
812	Pentoxifylline: A Drug with Antiviral and Anti-Inflammatory Effects to Be Considered in the Treatment of Coronavirus Disease 2019. 2021 , 30, 98-100	8
811	Development of vaccines and antivirals for combating viral pandemics. 2020 , 4, 1128-1133	27
810	Activation of Melanocortin Receptors as a Potential Strategy to Reduce Local and Systemic Reactions Induced by Respiratory Viruses. 2020 , 11, 569241	2
809	Viral Pandemics of the Last Four Decades: Pathophysiology, Health Impacts and Perspectives. 2020 , 17,	24
808	Liver transplant immunosuppression during the COVID-19 pandemic. 2020 , 43, 457-463	1
807	Testing and surveillance strategies in the context of COVID-19 in India. 2020 , 62, 343-350	1
806	Theoretical studies of the rotational and tautomeric states, electronic and spectroscopic properties of favipiravir and its structural analogues: a potential drug for the treatment of COVID-19. 2020 , 14, 1613-1625	5
805	COVID-19;-The origin, genetics,and management of the infection of mothers and babies. 2020 , 7, 371-388	
804	Biflavonoids from as probable natural inhibitors against SARS-CoV-2: a molecular docking and molecular dynamics approach. 2020 , 1-13	14
803	Geranii Herba as a Potential Inhibitor of SARS-CoV-2 Main 3CL, Spike RBD, and Regulation of Unfolded Protein Response: An In Silico Approach. 2020 , 9,	13
802	Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus. 2020 , 8,	11
801	SARS-CoV-2 M inhibitors: identification of anti-SARS-CoV-2 M compounds from FDA approved drugs. 2020 , 1-16	31

800	A Web-Based Platform on Coronavirus Disease-19 to Maintain Predicted Diagnostic, Drug, and Vaccine Candidates. 2020 , 39, 204-216	17
799	Emerging Molecular Prospective of SARS-CoV-2: Feasible Nanotechnology Based Detection and Inhibition. 2020 , 11, 2098	5
798	7-Hydroxy-4-phenyl-1, 2-dihydroquinoline derivatives: synthesis via one-pot, three-component reaction and structure elucidation. 2020 , 6, e05035	0
797	Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs. 2020 , 9,	22
796	A Chemographic Audit of anti-Coronavirus Structure-activity Information from Public Databases (ChEMBL). 2020 , 39, e2000080	8
795	Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. 2020 , 35, 101738	300
794	Potential therapeutic targets and promising drugs for combating SARS-CoV-2. 2020 , 177, 3147-3161	46
793	Why not consider an endothelin receptor antagonist against SARS-CoV-2?. 2020 , 141, 109792	5
792	COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2. 2020 , 7, 85	13
791	The Rationale for Potential Pharmacotherapy of COVID-19. 2020 , 13,	27
790	Three months of COVID-19: A systematic review and meta-analysis. 2020 , 30, e2113	25
789	Ethical and Sensible Dissemination of Information During the COVID-19 Pandemic. 2020 , 20, W4-W6	4
788	Artemisia annua: Trials are needed for COVID-19. 2020 , 34, 2423-2424	30
787	Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?. 2020 , 143, 109843	6
786	Psychopharmacology of COVID-19. 2020 , 61, 411-427	33
785	Covid-19 Pandemic and Current Medical Interventions. 2020 , 51, 473-481	9
784	Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing. 2020 , 287, 3664-3671	95
783	A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex. 2020 , 92, 2050-2054	134

782	Knowledge-based structural models of SARS-CoV-2 proteins and their complexes with potential drugs. 2020 , 594, 1960-1973	14
781	Validation and Psychometric Evaluation of the Italian Version of the Fear of COVID-19 Scale. 2020 , 1-10	188
780	Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. 2020 , 395, 1695-1704	948
779	Current development of COVID-19 diagnostics, vaccines and therapeutics. 2020 , 22, 231-235	34
778	Novel coronavirus 2019 (COVID-19): A case report and review of treatments. 2020 , 99, e20207	32
777	Covid-19 and drug therapy, what we learned. 2020 , 42, 833-836	7
776	Psychometric Validation of the Bangla Fear of COVID-19 Scale: Confirmatory Factor Analysis and Rasch Analysis. 2020 , 1-12	186
775	An Update on Current Therapeutic Drugs Treating COVID-19. 2020 , 6, 1-15	300
774	COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. 2020 , 53, 66-70	212
773	Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. 2020 , 142, 109783	29
772	"Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. 2020 , 75, 371-379	63
771	COVID-19: An Update on Clinical Trials. 2020 , 20, 1516-1517	
770	Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. 2020 , 256, 117883	62
769	The Potential Transmission of SARS-CoV-2 from Patients with Negative RT-PCR Swab Tests to Others: Two Related Clusters of COVID-19 Outbreak. 2020 , 73, 399-403	18
768	COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. 2020 , 11, 245-268	69
767	Statins and the COVID-19 main protease: evidence on direct interaction. 2020 , 16, 490-496	164
766	Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments. 2020 , 151, 102982	15
765	SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc. 2020 , 2, 100029	102

764	Fear of COVID-19 scale: Psychometric characteristics, reliability and validity in the Israeli population. 2020 , 289, 113100	220
763	Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic. 2020 , 86, 1790-1792	2
762	COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. 2020 , 5,	44
761	Characterization of the COVID-19 pandemic and the impact of uncertainties, mitigation strategies, and underreporting of cases in South Korea, Italy, and Brazil. 2020 , 136, 109888	67
760	Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings. 2020 , 79, 143-153	53
759	Fast and easy conversion of ortho amidoaryldiselenides into the corresponding ebselen-like derivatives driven by theoretical investigations. 2020 , 44, 9444-9451	7
758	COVID-19: Transmission, prevention, and potential therapeutic opportunities. 2020 , 508, 254-266	319
757	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. 2020 , 9, 435-449	35
756	Adaptation and evaluation of Turkish version of the fear of COVID-19 Scale. 2020 , 1-9	70
755	A role for retinoids in the treatment of COVID-19?. 2020 , 47, 1765-1767	29
754	COVID-19 in solid organ transplant recipients: a single-center experience. 2020 , 33, 1099-1105	56
753	COVID-19 and renal disease in elderly patients. 2020 , 6,	5
752	SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping. 2020 , 17, 21	46
751	Novel Coronavirus (COVID-19) Outbreak: Hope and Search for Effective Therapeutic Agent. 2020 , 17, 940-942	4
750	Full Issue PDF. 2020 , 5, I-CXXXVII	
749	Screening and druggability analysis of some plant metabolites against SARS-CoV-2: An integrative computational approach. 2020 , 20, 100367	28
748	Extensive hard palate hyperpigmentation associated with chloroquine use. 2020 , 86, 2325-2327	8
747	COVID19 inhibitors: A prospective therapeutics. 2020 , 101, 104027	15

746	Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies. 2020 , 14, 809-814	68
745	Fatal SARS-CoV-2 infection in a renal transplant recipient. 2020 , 9, 409-412	8
744	COVID-19 Drug Treatment in China. 2020 , 6, 1-9	7
743	Nanotechnology for COVID-19: Therapeutics and Vaccine Research. 2020 , 14, 7760-7782	172
742	Tackling SARS-CoV-2: proposed targets and repurposed drugs. 2020 , 12, 1579-1601	32
741	The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. 2020 , 43, 699-709	31
740	SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. 2020 , 178, 114114	46
739	COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. 2020 , 286, 198070	75
738	Azafluorene derivatives as inhibitors of SARS CoV-2 RdRp: Synthesis, physicochemical, quantum chemical, modeling and molecular docking analysis. 2020 , 1220, 128741	14
737	Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?. 2020 , 214, 107618	120
736	Can nanotechnology help in the fight against COVID-19?. 2020 , 18, 849-864	46
735	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review. 2020 , 19, 100	45
734	Risk of using hydroxychloroquine as a treatment of COVID-19. 2020 , 31, 111-116	17
733	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions. 2020 , 9,	38
732	Emergence of novel coronavirus and progress toward treatment and vaccine. 2020 , 30, e2116	6
731	Novel therapeutic approaches for treatment of COVID-19. 2020 , 98, 789-803	27
730	Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease. 2021 , 39, 3733-3746	26
729	SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. 2020 , 29, 973-987	68

728	Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19). 2020 , 27, 72	25
727	COVID-19 preclinical models: human angiotensin-converting enzyme 2 transgenic mice. 2020 , 14, 20	49
726	A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. 2020 , 201, 112527	52
725	Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. 2020 , 56, 106044	33
724	Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. 2020 , 117, 13967-13974	200
723	Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials. 2020 , 10, e039159	4
722	Systematic literature review on novel corona virus SARS-CoV-2: a threat to human era. 2020 , 31, 161-173	23
721	Liver transplant immunosuppression during the covid-19 pandemic. 2020 , 43, 457-463	12
720	Literature-based review of the drugs used for the treatment of COVID-19. 2020 , 10, 100-109	24
719	Full Issue PDF. 2020 , 2, I-CCXIV	
718	COVID-19, five months later. 2020 , 142,	1
717	Can mesenchymal stem cell therapy be the interim management of COVID-19?. <i>Drug Discoveries and Therapeutics</i> , 2020 , 14, 139-142	5 9
716	The laboratory's role in combating COVID-19. 2020 , 57, 400-414	26
715	Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of <i>Argemone mexicana</i> . 2020 , 144, 109905	16
714	Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review. 2020 , 1-14	16
713	COVID-19: from epidemiology to treatment. 2020 , 41, 2092-2112	45
712	Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov. 2020 , 14, 2159-2164	7
711	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. 2020 , 56, 106054	168

710	Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. 2020 , 11, 1648	201
709	Discovering small-molecule therapeutics against SARS-CoV-2. 2020 , 25, 1535-1544	61
708	Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?. 2020 , 7,	2
707	The Fear of COVID-19 Scale: Development and Initial Validation. 2020 , 1-9	1329
706	The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. 2020 , 214, 108393	787
705	SARS-CoV-2: What do we know so far?. 2020 , 229, e13470	10
704	Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. 2020 , 18, 1094-1099	2226
703	Coronavirus Disease (COVID-19) in Italy: Analysis of Risk Factors and Proposed Remedial Measures. 2020 , 7, 140	29
702	A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease. 2020 , 51, 337-342	79
701	Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. 2020 , 108, 242-247	220
700	COVID-19: Yet another coronavirus challenge in transplantation. 2020 , 39, 408-409	62
699	Current pharmacological treatments for SARS-COV-2: A narrative review. 2020 , 882, 173328	24
698	Drug targets for COVID-19 therapeutics: Ongoing global efforts. 2020 , 45, 1	54
697	Coronavirus lockdown helped the environment to bounce back. 2020 , 742, 140573	82
696	Predicting human microbe-drug associations via graph convolutional network with conditional random field. 2020 , 36, 4918-4927	31
695	The strategy for controlling COVID-19 in Kurdistan Regional Government (KRG)/Iraq: Identification, epidemiology, transmission, treatment, and recovery. 2020 , 25, 41-46	4
694	Vesicular drug delivery systems as theranostics in COVID-19. 2020 , 12, 1607-1609	11
693	Natural history of COVID-19 and current knowledge on treatment therapeutic options. 2020 , 129, 110493	59

692	SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. 2020 , 9,	29
691	Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. 2020 , 883, 173348	45
690	Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report. 2020 , 59, 102848	10
689	Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An Analysis. 2020 , 11, 1796	72
688	Interferon-beta: treatment option against COVID-19. 2020 , 6,	
687	Chloroquine: A Potential Drug in the COVID-19 Scenario. 2020 , 5, 399-410	7
686	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review. 2020 , 2, 1-6	25
685	COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection. 2020 , 9,	77
684	Ethical issues related to the hydroxychloroquine treatment prescription for Covid-19. 2020 , 14, 100547	2
683	Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. 2020 , 286, 198073	25
682	Acupuncture for breathlessness in COVID-19: A protocol for systematic review and meta-analysis. 2020 , 99, e20701	9
681	COVID-19: Emergence of Infectious Diseases, Nanotechnology Aspects, Challenges, and Future Perspectives. 2020 , 5, 7521-7533	21
680	Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. 2020 , 60, 1765-1772	40
679	Treatment of SARS-CoV-2: How far have we reached?. <i>Drug Discoveries and Therapeutics</i> , 2020 , 14, 67-725	25
678	Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. 2020 , 108, 766-769	34
677	Coronavirus Disease 2019 (COVID-19). 2020 ,	32
676	Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. 2020 , 26, 917-921	138
675	Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). 2020 , 26, 880-894	23

674	SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. 2020 , 27, 4536-4541	164
673	Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19. 2020 , 12,	76
672	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. 2020 , 9,	112
671	Nurture to nature via COVID-19, a self-regenerating environmental strategy of environment in global context. 2020 , 729, 139088	97
670	COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. 2020 , 5, 518-536	162
669	COVID-19: The Uninvited Guest in the Intensive Care Unit - Implications for Pharmacotherapy. 2020 , 40, 382-386	4
668	Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. 2020 , 40, 416-437	124
667	Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. 2020 , 39, 2055-2062	157
666	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. 2020 , 8, 506-517	812
665	The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. 2020 , 178, 104787	1103
664	Type 1 interferons as a potential treatment against COVID-19. 2020 , 178, 104791	333
663	Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. 2020 , 36, 948-951	85
662	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. 2020 , 215, 108409	142
661	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. 2020 , 2, 100113	280
660	Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy. 2020 , 124, 619-620	14
659	The Late Arrival of Coronavirus Disease 2019 (COVID-19) in Africa: Mitigating Pan-continental Spread. 2020 , 71, 875-878	39
658	Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease. 2021 , 39, 3099-3114	192
657	Current pharmacological treatments for COVID-19: What's next?. 2020 , 177, 4813-4824	137

656	COVID-19 Drug Discovery Using Intensive Approaches. 2020 , 21,	40
655	Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Monalizumab, Cholroquine, and antiviral agents. 2020 , 140, 109777	50
654	The old but new: Can unfractionated heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?. 2020 , 142, 109743	32
653	5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection. 2020 , 142, 109754	5
652	SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an perspective. 2021 , 39, 3204-3212	144
651	Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. 2020 , 323, 1824-1836	1402
650	Impact of Potential COVID-19 Treatment on South African Water Sources Already Threatened by Pharmaceutical Pollution. 2020 , 39, 1305-1306	15
649	SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. 2020 , 181, 1016-1035.e19	1326
648	Low dose radiation therapy for COVID-19 pneumonia: is there any supportive evidence?. 2020 , 96, 1224-1227	19
647	Anesthesia and COVID-19: What We Should Know and What We Should Do. 2020 , 24, 127-137	23
646	The intriguing features of COVID-19 in children and its impact on the pandemic. 2020 , 96, 265-268	2
645	Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India. 2020 , 728, 138914	118
644	Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. 2020 , 24, 6558-6570	59
643	Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. 2020 , 8, 497	89
642	COVID-19 in otolaryngologist practice: a review of current knowledge. 2020 , 277, 1885-1897	99
641	Management and Treatment of COVID-19: The Chinese Experience. 2020 , 36, 915-930	96
640	Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously. 2020 , 94, 107-109	140
639	Therapeutic management of patients with COVID-19: a systematic review. 2020 , 2, 100061	112

638	SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment. 2020 , 84, 106519	69
637	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities. 2020 , 5, 501-517	9
636	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities. 2020 , 2, 254-269	8
635	Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status. 2020 , 83, 104327	180
634	Overview of Covid-19; its prevention and management in the light of Unani medicine. 2020 , 728, 138859	36
633	Severe Pneumonia Due to SARS-CoV-2 and Respiratory Syncytial Virus Infection: A Case Report. 2020 , 59, 823-826	8
632	The intriguing features of COVID-19 in children and its impact on the pandemic. 2020 , 96, 265-268	27
631	The impact of coronavirus infectious disease 19 (COVID-19) on oral health. 2021 , 27 Suppl 3, 703-706	62
630	Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development. 2021 , 16, 4-23	30
629	Role of favipiravir in the treatment of COVID-19. 2021 , 102, 501-508	122
628	Effect of pre-existing diseases on COVID-19 infection and role of new sensors and biomaterials for its detection and treatment. 2020 , 4, e10140	4
627	Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?. 2021 , 76, 335-345	
626	Fighting the War Against COVID-19 via Cell-Based Regenerative Medicine: Lessons Learned from 1918 Spanish Flu and Other Previous Pandemics. 2021 , 17, 9-32	5
625	Antivirals for COVID-19: A critical review. 2021 , 9, 90-98	79
624	The rationale for a multi-step therapeutic approach based on antivirals, drugs and nutrients with immunomodulatory activity in patients with coronavirus-SARS2-induced disease of different severities. 2021 , 125, 275-293	6
623	Immunobiology and immunotherapy of COVID-19: A clinically updated overview. 2021 , 236, 2519-2543	30
622	Primed for global coronavirus pandemic: Emerging research and clinical outcome. 2021 , 209, 112862	10
621	Can human overcome viral hijack? Comprehensive review on COVID-19 in the view of diagnosis and mitigation across countries. 2021 , 61, 102120	1

620	COVID-19: Between Past and Present. 2021 , 34, 145-157	2
619	Evaluation of the effects of fear and anxiety on nutrition during the COVID-19 pandemic in Turkey. 2021 , 24, 282-289	16
618	A role for quercetin in coronavirus disease 2019 (COVID-19). 2021 , 35, 1230-1236	78
617	SARS-COV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments. 2021 , 39, 10-28	5
616	Coronavirus disease (COVID-19) prevention and treatment methods and effective parameters: A systematic literature review. 2021 , 64, 102568	45
615	Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19. 2021 , 48, 203-210	4
614	Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic. 2021 , 890, 173643	10
613	DFT calculations towards the geometry optimization, electronic structure, infrared spectroscopy and UV-vis analyses of Favipiravir adsorption on the first-row transition metals doped fullerenes; a new strategy for COVID-19 therapy. 2021 , 247, 119082	28
612	Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic. 2021 , 17, 1113-1121	4
611	Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2. 2021 , 23, 101-110	11
610	Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus. 2020 , 4, 2000203	6
609	COVID-19 lockdown: animal life, ecosystem and atmospheric environment. 2020 , 23, 1-18	18
608	Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoViTris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs. 2021 , 45, 761-771	18
607	C4 article: Implications of COVID-19 in transplantation. 2021 , 21, 1801-1815	7
606	An study on selected organosulfur compounds as potential drugs for SARS-CoV-2 infection binding multiple drug targets. 2021 , 763, 138193	19
605	Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs. 2021 , 128, 104117	56
604	Review of registered clinical trials for the treatment of COVID-19. 2021 , 82, 474-493	14
603	One year update on the COVID-19 pandemic: Where are we now?. 2021 , 214, 105778	70

602	The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options. 2021 , 150, 104673	45
601	Supervised Machine Learning Models for Prediction of COVID-19 Infection using Epidemiology Dataset. 2021 , 2, 11	73
600	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. 2021 , 41, 1375-1426	11
599	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. 2021 , 133, 111008	14
598	Development of an efficient, one-pot, multicomponent protocol for synthesis of 8-hydroxy-4-phenyl-1,2-dihydroquinoline derivatives. 2020 , 58, 534	
597	Understanding the temporal evolution of COVID-19 research through machine learning and natural language processing. 2020 , 126, 1-15	19
596	Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. 2021 , 103, 62-71	99
595	A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. 2021 , 384, 417-427	108
594	Global public health significances, healthcare perceptions of communities, treatments, prevention and control methods of COVID-19. 2021 , 29, 129-137	1
593	Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. 2021 , 102, 538-543	41
592	The effect of nationwide quarantine on anxiety levels during the COVID-19 outbreak in China. 2021 , 11, e01938	7
591	Therapeutic Approach against 2019-nCoV by Inhibition of ACE-2 Receptor. 2021 , 71, 213-218	7
590	Favipiravir and COVID-19: A Simplified Summary. 2021 , 71, 166-170	29
589	Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease. 2021 , 542, 111080	2
588	Potential SARS-CoV-2 main protease inhibitors. 2021 , 26, 804-816	52
587	Design of an epitope-based peptide vaccine against the SARS-CoV-2: a vaccine-informatics approach. 2021 , 22, 1309-1323	15
586	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. 2020 , 7, 585899	6
585	Self-medication practices during the COVID-19 pandemic among the adult population in Peru: A cross-sectional survey. 2021 , 29, 1-11	69

584	Natural and Synthetic Drugs as Potential Treatment for Coronavirus Disease 2019 (COVID-2019). 2021 , 4, 1-13	10
583	Biocatalytic routes to anti-viral agents and their synthetic intermediates. 2021 , 50, 1968-2009	13
582	The potential of ODFs as carriers for drugs/vaccines against COVID-19. 2021 , 47, 179-188	1
581	Combating COVID-19: The role of drug repurposing and medicinal plants. 2021 , 14, 495-503	16
580	COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel. 2021 , 93, e12977	10
579	Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019. 2021 , 10, 126-131	14
578	Management of SARS-CoV-2 pneumonia. 2021 , 93, 1276-1287	11
577	Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine. 2021 , 25, 13-22	5
576	Immune response and possible therapeutics in COVID-19.. 2020 , 11, 960-977	2
575	ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol. 2021 , 8, 119-123	1
574	Inhibition mechanism and hot-spot prediction of nine potential drugs for SARS-CoV-2 M by large-scale molecular dynamic simulations combined with accurate binding free energy calculations. 2021 , 13, 8313-8332	4
573	Introduction to the Virus and Its Infection Stages. 2021 , 1-26	
572	Scanning the VIRUS: A study of dimensions of stress and coping with COVID-19. 2021 , 1-11	8
571	Review of pharmacologic and immunologic agents in the management of COVID-19. 2021 , 3, 148-155	3
570	Covid 19-the 21st Century Pandemic: The Novel Coronavirus Outbreak and the Treatment Strategies.. 2022 , 12, 34-44	0
569	Modeling the structure of the frameshift-stimulatory pseudoknot in SARS-CoV-2 reveals multiple possible conformers. 2021 , 17, e1008603	13
568	Therapeutic targets and potential agents for the treatment of COVID-19. 2021 , 41, 1775-1797	11
567	Emerging therapeutics in the management of COVID-19. 2021 , 10, 1-29	2

566	Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19. 2021 , 25, 441-452	2
565	Influence of nanotechnology to combat against COVID-19 for global health emergency: A review. 2021 , 2, 100079	24
564	Two polymorphs of remdesivir: crystal structure, solubility, and pharmacokinetic study. 2021 , 23, 2923-2927	2
563	SARS-CoV-2 infection and smoking: What is the association? A brief review. 2021 , 19, 1654-1660	3
562	Airborne Infections and Emergency Surgery: The COVID-19 Pandemic Perspective. 2021 , 26, 76-88	0
561	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. 2021 , 27-89	
560	Treatment of COVID-19 by Combination Therapy with 5-fluorouracil, Ribonucleosides and Ribavirin: A Modified Strategy. 2021 , 571-581	
559	Computational Characterizations of the Interactions Between the Pontacyl Violet 6R and Exoribonuclease as a Potential Drug Target Against SARS-CoV-2. 2020 , 8, 627340	0
558	A crystallography-based investigation of weak interactions for drug design against COVID-19. 2021 , 23, 7261-7270	6
557	A comprehensive review of COVID-19 treatment. 2021 , 38, 105-115	1
556	The urgent need for pan-antiviral agents: from multitarget discovery to multiscale design. 2021 , 13, 5-8	6
555	Potential SARS-CoV-2 protease M inhibitors: repurposing FDA-approved drugs. 2021 , 18, 025001	2
554	In vitro screening of anti-viral and virucidal effects against SARS-CoV-2 by Hypericum perforatum and Echinacea.	2
553	Identification of potential antivirals against SARS-CoV-2 using virtual screening method. 2021 , 23, 100531	8
552	Viroinformatics for viral diseases: tools and databases. 2021 , 171-182	
551	Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein. 2021 , 11, e281	5
550	Topological Study of Hydroxychloroquine Conjugated Molecular Structure Used for Novel Coronavirus (COVID-19) Treatment. 1-17	8
549	In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19. 2021 , 32, 1-9	19

548	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. 2021 , 23, 14	93
547	The Balance between Two Branches of RAS Can Protect from Severe COVID-19 Course. 2021 , 15, 36-51	1
546	CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy. 2021 , 25, 1839-1854	13
545	Analysing the application of governance principles in the management of COVID-19 in South Africa: Lessons for the future. 2021 , 9,	1
544	Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. 2021 , 23, 5	8
543	Comparison of High-Resolution Computed Tomography and Real-Time Reverse Transcriptase Polymerase Chain Reaction in Diagnosis of COVID-19 Pneumonia in Intensive Care Unit Population. 2021 , 13, e13602	
542	Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection. 2021 , 70, 389-405	3
541	Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection. 2021 , 8, 628144	18
540	COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review. 2021 , 203, 2043-2057	4
539	Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted. 2021 , 8, 627723	9
538	A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation. 2021 , 22, 1476-1498	31
537	The Psychological Consequences of COVID-19 Fear and the Moderator Effects of Individuals' Underlying Illness and Witnessing Infected Friends and Family. 2021 , 18,	34
536	Cross Talk between COVID-19 and Breast Cancer. 2021 , 21, 575-600	4
535	Adjunctive Nutraceutical Therapies for COVID-19. 2021 , 22,	16
534	Immunopathogenesis and perspectives for immunotherapy of coronavirus infection. 2021 , 12, 7-22	0
533	Gestione del Covid-19 in et [^] pediatrica: documento di consenso. 2021 , 40, 85-101	4
532	Recent Advancement in SARS-CoV-2 Diagnosis, Treatment, and Vaccine Formulation: a New Paradigm of Nanotechnology in Strategic Combating of COVID-19 Pandemic. 2021 , 7, 1-14	9
531	Inflammatory Biomarkers and Chronic Diseases: The Link to COVID-19.. 1-8	

530	A Case Study: Analysis of Patents on Coronaviruses and Covid-19 for Technological Assessment and Future Research. 2021 , 27, 423-439	3
529	Remdesivir for the Treatment of COVID-19: A Need for Combined and Studies to Evaluate the Efficacy. 2021 , 34, 343-346	2
528	A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. 2021 , 12, 576448	5
527	Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study. 2021 , 45, 35-41	4
526	An overview of Covid-19 pandemic: immunology and pharmacology. 2021 , 42, 493-512	
525	The situation of small molecules targeting key proteins to combat SARS-CoV-2: Synthesis, metabolic pathway, mechanism of action, and potential therapeutic applications. 2021 ,	0
524	network-based analysis of drugs used against COVID-19: Human well-being study. 2021 , 28, 2029-2039	0
523	Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations. 2021 , 894, 173836	22
522	Investigation of structural, treatment and clinical characteristics of COVID-19 along with the challenges caused by its prevalence. 2021 ,	
521	A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment. 2021 , 130, 104186	10
520	Cellular Therapy as Promising Choice of Treatment for COVID-19.	
519	A potential peptide inhibitor of SARS-CoV-2 S and human ACE2 complex. 2021 , 1-11	1
518	Comparative study on quantum descriptors, molecular docking and dynamic simulation of antiviral drugs with Covid-19. 2021 , 30, 45-51	4
517	The Quixotic Task of Forecasting Peaks of COVID-19: Rather Focus on Forward and Backward Projections. 2021 , 9, 623521	5
516	Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2. 2021 , 12, 655528	5
515	Significance of deep learning for Covid-19: state-of-the-art review. 1	4
514	COVID-19 may enhance risk of thrombosis and hemolysis in the G6PD deficient patients. 2021 , 40, 505-517	4
513	Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2. 2021 , 12, 1517	24

512	Efficacy of ribavirin and interferon- β therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study. 2021 , 104, 641-648	21
511	Edible plant-derived exosomal microRNAs: Exploiting a cross-kingdom regulatory mechanism for targeting SARS-CoV-2. 2021 , 414, 115425	16
510	The Use of Primary Care Big Data in Understanding the Pharmacoepidemiology of COVID-19: A Consensus Statement From the COVID-19 Primary Care Database Consortium. 2021 , 19, 135-140	2
509	Computational evidence for nitro derivatives of quinoline and quinoline N-oxide as low-cost alternative for the treatment of SARS-CoV-2 infection. 2021 , 11, 6397	8
508	The find of COVID-19 vaccine: Challenges and opportunities. 2021 , 14, 389-416	18
507	A Review on Repurposed Drugs and Vaccine Trials for Combating SARS CoV-2. 2021 , 13, 203-221	1
506	COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact-an updated review. 2021 , 28, 22241-22264	15
505	COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. 2021 , 17, 24	7
504	Exploring the new potential antiviral constituents of Moringa oliefera for SARS-COV-2 pathogenesis: An molecular docking and dynamic studies. 2021 , 767, 138379	22
503	Psychosocial Impact of COVID-19 on Healthcare Workers: A cross-sectional survey from Pakistan.. 2022 , 22, 82-90	0
502	Association of built environment attributes with the spread of COVID-19 at its initial stage in China. 2021 , 67, 102752	37
501	Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review. 2021 , 150, 112087	10
500	The role of nanotechnology in current COVID-19 outbreak. 2021 , 7, e06841	16
499	Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. 2021 , 24, 102367	34
498	No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. 2021 , 897, 173947	31
497	Simultaneous electrochemical detection of azithromycin and hydroxychloroquine based on VS QDs embedded N, S @graphene aerogel/cCNTs 3D nanostructure. 2021 , 163, 105925	12
496	Advances in immunotherapy for COVID-19: A comprehensive review. 2021 , 93, 107409	9
495	Present and future treatment strategies for coronavirus disease 2019. 2021 , 7, 84	7

494	Antiviral activity of bioactive phytocompounds against coronavirus: An update. 2021 , 290, 114070	11
493	COVID-19 prediction using AI analytics for South Korea. 2021 , 1-19	6
492	Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. 2021 , 17, 371-387	31
491	An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. 2021 , 6, 165	40
490	Epidemiology, Risk, Myths, Pharmacotherapeutic Management and Socio- economic Burden due to Novel COVID-19: A Recent Update. 2021 , 2308-2315	1
489	COVID-19: A Review on Epidemiology, Clinical Features and Possible Potential Drugs Based on Available Case Studies. 2021 , 2, 299-312	2
488	In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants. 2021 , 16, 162-176	13
487	A Systematic Review on Various Therapeutic Options for Coronavirus Outbreak. 2021 , 11, 185-194	
486	SARS-CoV-2 Entry inhibitors targeting virus-ACE2 or virus-TMPRSS2 interactions. 2021 ,	1
485	An Overview of the Treatment Contributions Measured Globally for the COVID-19 Outbreak. 2021 , 2, 198-203	0
484	Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses. 2021 , 11, 8692	9
483	Global economic crisis, energy use, CO emissions, and policy roadmap amid COVID-19. 2021 , 26, 770-781	52
482	Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. 2021 , 2021, 6631721	11
481	The value of interferon therapy for COVID-19 in children. 2021 , 20, 34-38	0
480	Dissecting lipid metabolism alterations in SARS-CoV-2. 2021 , 82, 101092	27
479	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. 2021 ,	
478	Genetically Engineered Live-Attenuated Middle East Respiratory Syndrome Coronavirus Viruses Confer Full Protection against Lethal Infection. 2021 , 12,	3
477	Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient. 2021 , 60, 1115-1117	1

476	COVID-19 Management in the Pediatric Age: Consensus Document of the COVID-19 Working Group in Paediatrics of the Emilia-Romagna Region (RE-CO-Ped), Italy. 2021 , 18,	13
475	Drugs intervention study in COVID-19 management. 2021 ,	4
474	Coronavirus Disease 2019: An Overview of the Complications and Management. 1-28	
473	Are countries' precautionary actions against COVID-19 effective? An assessment study of 175 countries worldwide. 2021 , 29, 391-409	2
472	COVID-19: breaking down a global health crisis. 2021 , 20, 35	43
471	A Mini Review: Origin, Treatments, Preventions, Real Facts and Viability of the Recent Pandemic of Novel Coronavirus-2019. 2021 , 2,	
470	Discovery of (4-cyanobenzylidene)- 6-fluoro- 3-hydroxypyrazine-2 -carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug. 2021 , 75, 1-17	10
469	COVID-19 recovery rate and its association with development. 73, 8-14	1
468	Exploring status of emergency drugs and vaccine development in Covid-19 pandemic: an update. 2021 , 32, 1-13	3
467	Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies. 2021 , 35, e22795	1
466	Practicing With Uncertainty: Kidney Transplantation During the COVID-19 Pandemic. 2021 , 77, 777-785	17
465	Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials. 2021 , 21, 1123-1143	3
464	Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. 2021 , 87, 4421-4431	4
463	The Therapeutic Effect of Traditional Chinese Medicine on Inflammatory Diseases Caused by Virus, Especially on Those Caused by COVID-19. 2021 , 12, 650425	0
462	The Chronicle of COVID-19 and Possible Strategies to Curb the Pandemic. 2021 , 28, 2852-2886	9
461	The 15-Months Clinical Experience of SARS-CoV-2: A Literature Review of Therapies and Adjuvants. 2021 , 10,	11
460	Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines. 2021 , 137, 111330	13
459	SARS-CoV-2: From the pathogenesis to potential anti-viral treatments. 2021 , 137, 111352	14

458	Current Overviews on COVID-19 Management Strategies. 2021 ,	3
457	Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response. 2021 , 7,	9
456	Current Pharmaceutical Aspects of Synthetic Quinoline Derivatives. 2021 , 21, 1152-1172	3
455	Computational insights of phytochemical-driven disruption of RNA-dependent RNA polymerase-mediated replication of coronavirus: a strategic treatment plan against coronavirus disease 2019. 2021 , 41, 100878	2
454	Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies. 2021 , 137, 111356	13
453	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. 2021 , 14,	10
452	Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants. 2021 , 133, 104362	8
451	Advanced Applications of Fuel Cells during the COVID-19 Pandemic. 2021 , 2021, 1-9	2
450	An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia. 2021 , 16, e0252302	7
449	A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials. 2021 , 8, 637378	7
448	A Multidisciplinary Approach to Coronavirus Disease (COVID-19). 2021 , 26,	3
447	Chloroquine as Chemoprophylaxis for COVID-19: Will This Work. 2021 , 21, 473-474	9
446	The COVID-19 pandemic face mask waste: A blooming threat to the marine environment. 2021 , 272, 129601	72
445	Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications. 2021 , 12, 582556	2
444	An overview of basic molecular biology of SARS-CoV-2 and current COVID-19 prevention strategies. 2021 , 23, 101122	7
443	The Current Outbreak of COVID-19 with Reference to India. 2021 , 2, 448-459	
442	The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy. 2021 , 21, 514-526	5
441	Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach. 2021 , 138, 111544	16

440	The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. 2021 , 10, 100085	5
439	An Overview of the Epidemiologic, Diagnostic and Treatment Approaches of COVID-19: What do We Know?. 2021 , 42, 1604061	2
438	Origin, Pathogenesis, Diagnosis and Treatment Options for SARS-CoV-2: A Review. 2021 , 76, 1-19	5
437	Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID). 2021 , 22,	7
436	Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial. 2021 , 43, 1007-1019	22
435	Immunosuppressant Drugs And Covid-19: Associated Risks, Drug-Drug Interactions & Contraindications. 2021 , 02,	
434	Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN- as a Novel Antiviral Approach Against COVID-19. 2021 , 34, 321-329	2
433	Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA). 2021 , 1	0
432	COVID-19 Hastalarda Tedaviye Başlı Karaciğer Hasar-Gelişim Skali Favipiravir bu Tabloda ne Kadar Etkili?. 338-343	0
431	Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study. 2021 , 16, e0252984	9
430	Impacts of COVID-19 pandemic on the wastewater pathway into surface water: A review. 2021 , 774, 145586	21
429	A patient presenting with ARDS after COVID-19 vaccination: A COVID-19 case report. 2021 , 14, 1395-1397	1
428	A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase. 2021 , 181, 605-611	9
427	Neurological Effects of Sars-Cov-2 And Neurotoxicity of Antiviral Drugs Against Covid-19. 2021 ,	1
426	Nanotechnology-Based Approach to Combat Pandemic COVID 19: A Review. 2021 , 397, 2000336	1
425	Targeted Delivery of CRISPR/Cas13 as a Promising Therapeutic Approach to Treat SARS-CoV-2. 2021 , 22, 1149-1155	7
424	Emergence of a New Zoonotic COVID-19 that Creates a Pandemic: Update on Current Pharmacotherapeutics and Future Prospective of Plasma Therapy. 2021 , 2, 422-430	
423	Favipiravir: insight into the crystal structure, Hirshfeld surface analysis and computational study. 1	7

422	Structure Based Drug Design Approach to Identify Potential SARS-CoV-2 Polymerase Inhibitors. 2021 , 2, 507-515	0
421	Off Label Medication to Combat COVID-19: Review Results to Date. 2021 , 2, 496-506	
420	Therapeutic approaches to tackle COVID-19: An overview. 2021 , 8, 121-135	
419	Attitudes and Acceptance of COVID-19 Vaccination Among Nurses and Midwives in Cyprus: A Cross-Sectional Survey. 2021 , 9, 656138	19
418	The scientific community in COVID-19 global pandemic: A systematic update on recent progress and challenges. 2021 , 12, 222-234	
417	Current Treatments and Therapeutic Options for COVID-19 Patients: A Systematic Review. 2021 ,	1
416	COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach. 2021 , 15, 3313-3330	2
415	The Islamic principle of (protection of life) and COVID-19 in Indonesia: A case study of nurul iman mosque of Bengkulu city. 2021 , 7, e07541	1
414	Withdrawal Notice: Nanotechnology-Based Approaches and Investigational Therapeutics against COVID-19. 2021 ,	2
413	Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles. 2021 , 343, 109480	8
412	COVID Detection via Nanotechnology: A Promising Field in the Diagnosis and Analysis of Novel Coronavirus Infection. 2021 , 57-73	1
411	Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. 2021 , 139, 111642	19
410	A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine. 2021 , 152, 110619	0
409	Tracing the Pace of COVID-19 Research: Topic Modeling and Evolution. 2021 , 25, 100236	2
408	A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019. 2021 , 42, 100895	2
407	Theranostic Approach for Coronavirus. 2021 , 261-274	
406	Potential Inhibition of COVID-19 RNA-dependent RNA Polymerase by Hepatitis C Virus Non-nucleoside Inhibitors: An In-silico Perspective. 2021 , 18, 429-435	1
405	Fear and depressive symptoms amid COVID-19: A cross-sectional pilot study among adult population in Bangladesh. 2021 , 7, e07395	5

404	A decision-tree approach to treat platelet hyperactivity and anomalous blood clotting in acute COVID-19 patients.	
403	Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly. 2021 , 29, 1033-1048	6
402	Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study. 2021 , 11, 05017	1
401	Comparison of Clinical and Laboratory Features and Treatment Options of 237 Symptomatic and Asymptomatic Children Infected with SARS-CoV-2 in the Early Phase of the COVID-19 Pandemic in Turkey. 2021 , 74, 273-279	3
400	Diagnosis, prevention, and treatment of coronavirus disease: a review. 2021 , 1-24	1
399	Exploring Phytochemicals of Traditional Medicinal Plants Exhibiting Inhibitory Activity Against Main Protease, Spike Glycoprotein, RNA-dependent RNA Polymerase and Non-Structural Proteins of SARS-CoV-2 Through Virtual Screening. 2021 , 12, 667704	10
398	A dossier on COVID-19 chronicle. 2021 ,	2
397	Interference of Polydatin/Resveratrol in the ACE2:Spike Recognition during COVID-19 Infection. A Focus on Their Potential Mechanism of Action through Computational and Biochemical Assays. 2021 , 11,	12
396	Ivermectin for Coronavirus Disease 2019: Yet to Be Well Evaluated Before Clinical Use. 2021 , 43, 1622-1623	1
395	An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system. 2021 , 45, 123	1
394	Network-Based Analysis of Fatal Comorbidities of COVID-19 and Potential Therapeutics. 2021 , 18, 1271-1280	10
393	Simple Classification of RNA Sequences of Respiratory-Related Coronaviruses. 2021 , 6, 20158-20165	
392	Synopsis of Pharmotechnological Approaches in Diagnostic and Management Strategies for Fighting Against COVID-19. 2021 , 27, 4086-4099	0
391	Nanotechnology Integration for SARS-CoV-2 Diagnosis and Treatment: An Approach to Preventing Pandemic. 2021 , 11,	6
390	Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins. 2021 , 28, 18	4
389	Heterogeneous graph attention networks for drug virus association prediction. 2021 , 198, 11-11	0
388	Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. 2021 , 58, 106428	2
387	Role of Anti-Viral Drugs in Combating SARS-CoV-2.	

386	COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. 2021 , 60, 28-45	9
385	Chloroquine and pyrimethamine inhibit the replication of human respiratory syncytial virus A. 2021 , 102,	0
384	Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach. 2021 , 140, 111742	8
383	The Role of ACE2 Receptors of the Olfactory System in Anosmia in COVID-19: An Overview. 2021 , 2021, 5776801	
382	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. 2021 , 6, 317	17
381	Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection. 2021 , 10,	5
380	Metal doped fullerene complexes as promising drug delivery materials against COVID-19. 2021 , 1-11	5
379	Medicinal plants as immune booster in the palliative management of viral diseases: A perspective on coronavirus.	2
378	Structural bioinformatics used to predict the protein targets of remdesivir and flavones in SARS-CoV-2 infection. 2021 ,	
377	Combination of natural antivirals and potent immune invigorators: A natural remedy to combat COVID-19. 2021 ,	5
376	An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks. 2021 , 10,	7
375	Estimating spatiotemporal patterns of deaths by COVID-19 outbreak on a global scale. 2021 , 11, e047002	1
374	Atrial Fibrillation as a Predictor of Mortality in High Risk COVID-19 Patients: A Multicentre Study of 171 Patients. 2021 , 30, 1151-1156	4
373	Does compliance with the preventive health behaviours against COVID-19 mitigate the effects of depression, anxiety and stress? (¿Cumplir con los comportamientos preventivos de salud contra el COVID-19 reduce los efectos de la depresión, la ansiedad y el estrés?). 1-25	0
372	Clinical outcome of patients with COVID-19 Pneumonia treated with corticosteroids and colchicine in Colombia. 2021 , 20, 66	5
371	Repurposing fusion inhibitor peptide against SARS-CoV-2. 2021 , 42, 2283-2293	2
370	Cyanorona-20: The first potent anti-SARS-CoV-2 agent. 2021 , 98, 107831	12
369	Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights. 2021 ,	2

368	COVID-19 Infection in Children, Infants and Pregnant Subjects: An Overview of Recent Insights and Therapies. 2021 , 9,	4
367	Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. 2021 , 12, 683296	16
366	Roles of existing drug and drug targets for COVID-19 management. 2021 , 11, 100103	3
365	An analysis model of diagnosis and treatment for COVID-19 pandemic based on medical information fusion. 2021 , 73, 11-21	5
364	Coronavirus disease 2019 and renal transplantation. 2021 , 9, 7986-7997	0
363	Ensembles of Convolutional Neural Network models for pediatric pneumonia diagnosis. 2021 , 122, 220-233	8
362	The Role of Nanotechnology in Antiviral Regime: An Overview. 2130011	1
361	Deciphering the key heterocyclic scaffolds in targeting microtubules, kinases and carbonic anhydrases for cancer drug development. 2021 , 225, 107860	9
360	Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2. 2021 , 1-27	3
359	Emerging nanotechnology role in the development of innovative solutions against COVID-19 pandemic. 2021 , 32,	0
358	The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. 2021 , 1, 15	1
357	Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis. 2021 , 28, 59570-59593	5
356	Changes in fears and worries related to COVID-19 during the pandemic among current employees in Japan: a 5-month longitudinal study. 2021 , 198, 69-74	3
355	Historical Perspective on the Discovery of the Quasispecies Concept. 2021 , 8, 51-72	10
354	Alcohol use disorder in the COVID-19 era: Position paper of the Italian Society on Alcohol (SIA). 2021 , e13090	3
353	Discovery of novel oxazole-based macrocycles as anti-coronaviral agents targeting SARS-CoV-2 main protease. 2021 , 116, 105363	3
352	Robust trend estimation for COVID-19 in Brazil. 2021 , 39, 100455	2
351	The potential of BEN815 as an anti-inflammatory, antiviral and antioxidant agent for the treatment of COVID-19.. 2021 , 1, 100058	1

350	Discovery of Taroxaz-104: The first potent antidote of SARS-CoV-2 VOC-202012/01 strain. 2021 , 1246, 131106	7
349	Emerging Potential of Metallodrugs to Target Coronavirus: Efficacy, Toxicity and their Mechanism of Action. 2021 , 33, 1191-1207	0
348	Socio-environmental factors affecting mental health of people during Covid-19 in coastal urban areas of Bangladesh. 2021 , 49-62	2
347	Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin. 2021 , 26,	14
346	A Comprehensive Summary of the Knowledge on COVID-19 Treatment. 2021 , 12, 155-191	13
345	Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2. 2021 , 2, 100026	4
344	Inhibitory activity of quercetin, its metabolite, and standard antiviral drugs towards enzymes essential for SARS-CoV-2: the role of acid-base equilibria.. 2021 , 11, 2838-2847	19
343	COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. 2021 , 18, 754-771	58
342	New Technical Using Nano in Medical Field to Determine Medications that are Suitable Activities for COVID-19. 2021 , 917-921	1
341	Are Patients with Asthma and Chronic Obstructive Pulmonary Disease Preferred Targets of COVID-19?. 2021 , 84, 22-34	6
340	An update of coronavirus disease 2019 (COVID-19): an essential brief. 2021 , 4, 19-38	
339	The effect of the COVID-19 pandemic on community mental health: A psychometric and prevalence study in Turkey. 2021 , 29, e204-e213	5
338	Review of investigational drugs for coronavirus disease 2019. 2021 , 10, 31	4
337	Prescription, over-the-counter (OTC), herbal, and other treatments and preventive uses for COVID-19. 2021 , 379-416	7
336	Flattening the curves: on-off lock-down strategies for COVID-19 with an application to Brazil. 2021 , 11, 2	11
335	Natural products as environmentally safe and green approach to combat Covid-19. 2021 , 4, 100114	2
334	The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus. 2021 , 23, 100529	3
333	Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview. 2021 , 9, e00705	17

332	Current Insight into the Novel Coronavirus Disease 2019 (COVID-19). 2020 , 1-8	10
331	Preparing for the Perpetual Challenges of Pandemics of Coronavirus Infections with Special Focus on SARS-CoV-2. 2020 , 165-186	6
330	Differential Diagnosis and Possible Therapeutics for Coronavirus Disease 2019. 2020 , 51-71	1
329	Role of Computational Intelligence Against COVID-19. 2021 , 19-43	2
328	COVID-19 therapy: What weapons do we bring into battle?. 2020 , 28, 115757	12
327	Biomedical application, drug delivery and metabolic pathway of antiviral nanotherapeutics for combating viral pandemic: A review. 2020 , 191, 110119	19
326	Nanotheranostics against COVID-19: From multivalent to immune-targeted materials. 2020 , 328, 112-126	22
325	Current Insights into the Novel Coronavirus Disease 2019 (COVID-19) and Its Homoeopathic Management. 2020 , 33, 171-179	3
324	Natural history of COVID-19 and therapeutic options. 2020 , 16, 1159-1184	41
323	Coronavirus disease 2019 in chronic kidney disease. 2020 , 13, 297-306	29
322	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. 2020 , 42, 360-368	25
321	The COVID-19 Pandemic: Changing Lives and Lessons Learned. 2020 , 8, e2854	19
320	Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial.	278
319	Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.	12
318	Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19 Infection- A Systematic Literature Review.	14
317	A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between gender.	17
316	Countrywide quarantine only mildly increased anxiety level during COVID-19 outbreak in China.	9
315	Therapeutic Management of COVID-19 Patients: A systematic review.	11

314	Rapid in silico design of antibodies targeting SARS-CoV-2 using machine learning and supercomputing.	12
313	Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study.	12
312	Multidrug treatment with nelfinavir and cepharanthine against COVID-19.	35
311	Favipiravir for treating novel coronavirus (COVID-19) patients: protocol for a systematic review and meta-analysis of controlled trials.	4
310	Design of an Epitope-Based Peptide Vaccine against the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): A Vaccine-informatics Approach.	6
309	Toxicity Studies and Inactivation of SARS-CoV-2 by Povidone-iodine Gel Forming Formulations. 2020,	10
308	Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets.	1
307	Global research trend in the treatment of the new Coronavirus diseases (COVID-19): bibliometric analysis.	1
306	A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease.	17
305	Efficacy of Targeting SARS-CoV-2 by CAR-NK Cells. 2020,	11
304	Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells. 2020,	8
303	Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China. 2020, 18, 1559325820970921	
302	An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development. 2020, 26, e924700	108
301	The interface of psychiatry and COVID-19: Challenges for management of psychiatric patients. 2020, 36, 1133-1136	4
300	Antiviral treatment of COVID-19: a clinical pharmacology narrative review. 2020, 29, 332-45	5
299	COVID-19, Modern Pandemic: A Systematic Review From Front-Line Health Care Providers' Perspective. 2020, 12, 215-229	31
298	Adjunctive favipiravir for severe COVID-19: a retrospective observational study of the first 41 patients in Thailand. 2020, 14, 107-110	1
297	Clinical management of coronavirus disease 2019 (COVID-19) in pregnancy: recommendations of WAPM-World Association of Perinatal Medicine. 2020, 48, 857-866	15

296	COVID-19 therapy and prevention. 2020 , 8, e113	3
295	COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. 2020 , 8, e108	26
294	Evaluation of knowledge and attitudes among intensive care physicians during the COVID-19 pandemic: a cross-sectional survey. 2020 , 138, 317-321	6
293	Fighting COVID-19. 2020 , 80, 698-701	3
292	Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review. 2020 , 66, 842-848	17
291	The COVID-19 Pandemic - A Global Public Health Crisis: A Brief Overview Regarding Pharmacological Interventions. 2020 , 20,	8
290	An Up-to-Date Overview of Therapeutic Agents for the Treatment of COVID-19 Disease. 2020 , 12, 203-212	2
289	Current Scenario and Future Prospect in the Management of COVID-19. 2021 , 28, 284-307	13
288	Recent Advances in Transition Metal Free Synthetic Protocols for Quinoline Derivatives. 2020 , 24, 1815-1852	2
287	Therapeutic Targets and Computational Approaches on Drug Development for COVID-19. 2020 , 20, 2210-2220	11
286	Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review. 2020 , 22, e20193	26
285	The Anatomy of the SARS-CoV-2 Biomedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation. 2020 , 22, e21169	9
284	A Review of Potential Antiviral Drugs and Vaccines to Treat COVID-19. 2020 , 14, 765-774	1
283	SARS-CoV-2 / COVID-19 and its Transmission, Prevention, Treatment and Control - An Update. 2020 , 14, 945-956	1
282	COVID19: potential cardiovascular issues in pediatric patients. 2020 , 91, 177-183	14
281	Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies. 2021 , 71, 163-174	15
280	FAVIPIRAVIR AS A POTENTIAL DRUG IN THE TREATMENT OF COVID-19. 2020 , 8, 7-12	4
279	Role of nanotechnology in diagnosing and treating COVID-19 during the Pandemi. 2020 , 4, 065-070	14

278	Relationship between COVID-19 and liver diseases: the role of hepatologists in clinical practice. 2020 , 61, 496-503	1
277	A Narrative Review of COVID-19: The New Pandemic Disease. 2020 , 45, 233-249	18
276	The COVID-19 Pandemic through the Lens of Education in the Philippines: The New Normal. 2020 , 1, ep2001	28
275	Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection. 2020 , 61, 826-830	10
274	The Role of Extracellular Vesicles as Allies of HIV, HCV and SARS Viruses. 2020 , 12,	18
273	Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic. 2020 , 8,	55
272	Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. 2020 , 4,	61
271	Combating the Coronavirus Pandemic: Early Detection, Medical Treatment, and a Concerted Effort by the Global Community. 2020 , 2020, 6925296	12
270	Spreadable Virus of the 21st Century: COVID-19. 2020 , 21, 13-18	1
269	[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. 2020 , 20, 147-150	4
268	Confronting the threat of SARS-CoV-2: Realities, challenges and therapeutic strategies (Review). 2021 , 21, 155	2
267	Interim Guidelines on Antiviral Therapy for COVID-19. 2020 , 52, 281-304	23
266	Palestinian strategies, guidelines, and challenges in the treatment and management of coronavirus disease-2019 (COVID-19). 2020 , 10, 135-162	4
265	COVID-19 and its impact on genitourinary malignancies. 2020 , 36, 163-170	4
264	Herbs that might be effective for the management of COVID-19: A bioinformatics analysis on anti-tyrosine kinase property. 2020 , 25, 44	7
263	Current status of COVID-19 pandemic; characteristics, diagnosis, prevention, and treatment. 2020 , 25, 101	5
262	Combating 2019-nCoV Amidst the Pandemic Scare. 2020 , 09, 15-19	3
261	The Pandemic COVID-19 and the Auspicious Role of Frontier Pharmacists against This Global Threat. 2020 , 11, 209-225	1

260	Current Approaches to COVID-19: Therapy and Prevention. 2020 , 24, 838-846	10
259	The COVID-19 pandemic: Clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists. 2020 , 31, 348-355	2
258	Post-transplant immunosuppression and COVID-19: From a double whammy to a mixed blessing. 2020 , 10, 267-276	3
257	Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China. 2021 , 14, 408-414	2
256	An overview of potential therapeutic agents to treat COVID-19. 2020 , 14, 318-327	4
255	Dental Considerations After the Outbreak of 2019 Novel Coronavirus Disease: A Review of Literature. 2020 , 15,	9
254	Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis. 2020 , 16, 301-306	22
253	A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19). 2020 , 12, e7560	243
252	Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials. 2020 , 12, e8342	24
251	Chloroquine and COVID-19 - a potential game changer?. 2020 ,	14
250	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. 2021 , 1313, 99-134	1
249	Current Status of COVID-19 Diagnostics.	
248	Determination of Favipiravir from Pharmaceutical Dosage Form by Extractive Ion Pair Complex Colorimetric Method. 2021 , 321-323	3
247	The Interactive Effect of COVID-19 Risk and Hospital Measures on Turnover Intentions of Healthcare Workers: A Time-Lagged Study. 2021 , 18,	3
246	Cross-talk between immune system and microbiota in COVID-19. 2021 , 15, 1281-1294	9
245	A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol. 2021 , 22, 674	3
244	Do interferons play a role in COVID-19?. 2021 , 75, e14721	0
243	Chemical Composition, in-vitro Antioxidant, Antibacterial, and Anti-algal Activity of Lakshadweep Feather Star Spp. Comaster Schlegelii and Himerometra Robustipinna. 1	0

- 242 Multisystemic inflammatory syndrome in children with COVID-19: A rheumatology perspective. **2021**, 28, 289-289
- 241 Current trends in diagnosis and treatment strategies of COVID-19 infection. **2021**, 28, 64987-65013 2
- 240 Current treatment strategies for COVID-19 (Review). **2021**, 24, 2
- 239 Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments. **2021**, 28, 68071 4
- 238 PAMAM and polyester dendrimers as favipiravir nanocarriers: a comparative study using DFT method. **2021**, 23, 231 5
- 237 Drugs and liver injury: a not to be overlooked binomial in COVID-19. **2021**, 1-14 1
- 236 A deep learning ensemble approach to prioritize antiviral drugs against novel coronavirus SARS-CoV-2 for COVID-19 drug repurposing. **2021**, 113, 107945 1
- 235 Anti-corona Drugs: Current Scenario. **2020**, 30, 179-184
- 234 Generalidades, manejos, cuidados y manifestaciones clínicas del SARS-CoV-2.. **2020**, 77, 153-155 1
- 233 Bioactive Constituents and Pharmacological Activities. **2020**, 59-95 1
- 232 Pharmacological Aspects and Clues for the Rational Use of Chloroquine / Hydroxychloroquine Facing the Therapeutic Challenges of COVID-19 Pandemic. **2020**, 2, 28-34 2
- 231 Going by the Numbers : Learning and Modeling COVID-19 Disease Dynamics. 1
- 230 Emerging Pharmaceutical Treatments of Novel COVID-19: A Review. **2020**, 12, e8260 3
- 229 Mesenchymal Stromal Cell Therapy For Critically Ill Patients With COVID-19 (Preprint).
- 228 Treatments administered to the first 9,152 reported cases of COVID19: a systematic review.
- 227 Revisiting early-stage COVID-19 strategy options. **2020**, 9, 327
- 226 Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review (Preprint).
- 225 Combating Outbreak of nCoV-19: Prevention Strategies, Possible Medication and Its Predominance in Pakistan. **2020**, 39-45

224	Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies. <i>Drug Discoveries and Therapeutics</i> , 2020 , 14, 109-116	5	2
223	The Anatomy of SARS-CoV-2 BioMedical Literature: Introducing the CovidX Network Algorithm for Drug Repurposing Recommendation (Preprint).		
222	Global research trend in the treatment of the new Coronavirus diseases (COVID-19) : bibliometric analysis. (Preprint).		
221	Revisiting early-stage COVID-19 strategy options. 9, 327		1
220	Covid-19 Pandemic-Insights and Challenges. 2020 , 1, 070-087		
219	Telehealth and Pharmacological Strategies of COVID-19 Prevention: Current and Future Developments. 2022 , 897-927		
218	Immunosuppression for liver transplant recipients during the COVID-19 pandemic. 2021 ,		
217	Covid-19 Pandemic and Coronaviruses from Discovery to Treatment: A Tale of Two Decades of 21st Century. 2022 , 1065-1095		
216	Robust Statistical Modeling of COVID-19 Prevalence in African Epicentres□ 2022 , 315-358		0
215	Severe Fever with Thrombocytopenia Syndrome: Japan under Threat from Life-threatening Emerging Tick-borne Disease. 2020 , 3, 295-302		2
214	Alterations in Peripheral Lymphocyte Subsets in Early Stage of Novel Coronavirus Pneumonia.		
213	Chloroquine Phosphate is not Proved to be an Effective Treatment for Coronavirus: A Meta-analysis of Clinical Trials. 2020 , 14, 310-311		
212	Therapeutic Approach Against 2019-nCoV by Inhibition of the ACE-2 receptor. 2020 ,		1
211	Novel Coronavirus (covid-19) a Ubiquitous Hazard to Human Health: A Review. 2020 , 20, 185-195		
210	Treatment of COVID-19 with Chloroquine: Implication for Malaria Chemotherapy Using ACTs in Disease Endemic Countries. 2021 , 67,		
209	Covid-19: The Biggest Threat of the 21 Century: In Respectful Memory of the Warriors All Over the World. 2020 , 21, 409-418		2
208	Pharmacodynamics of Remdesivir: How to Improve for COVID-19 Treatment. 2020 , 1, 431-438		1
207	Therapy of patients with COVID-19: clinical studies and recommendations in different countries. 2020 , 5-12		1

- 206 The specificity of the novel coronavirus infection in transplantation recipients. **2020**, 31, 1448-1450
- 205 nCOVID-19: Its diagnosis, possible preventive measures, therapeutic interventions and management. **2020**, 115-129
- 204 El proceso de vacunación en México.. **2021**, 78, 270-274 1
- 203 Simulation Study on Effect of Lockdown and Recovery Time on Spread of COVID-19 in High and Low-Density Areas.
- 202 Familiar fixes for a modern malady: a discussion on the possible cures of COVID-19. **2020**, 7, 269-280 0
- 201 Rational Drug Usage Suggestion for COVID-19 Patients at Prime Stage. **2020**, 09, 181-185
- 200 Development of the Indian scale of the fear of COVID-19. **2020**, 29, 47-50
- 199 Utility of convalescent plasma for COVID-19 treatment. **2020**, 7, 166
- 198 Theoretical insights into the effect of halogenated substituent on the electronic structure and spectroscopic properties of the favipiravir tautomeric forms and its implications for the treatment of COVID-19.. **2021**, 11, 35228-35244 0
- 197 Efficacy of remdesivir versus placebo for the treatment of COVID-19: A protocol for systematic review and meta-analysis of randomized controlled trials. 1
- 196 Recent scientific research progress and challenges of COVID-19 pandemic: a global public health event.
- 195 FARMACOS ANTIMICROBIANOS E ANTIVIRAIS COM POTENCIAL USO TERAPÉUTICO PARA A COVID-19. **2020**, 32, 109-119
- 194 SARS-CoV-2, the Tiny Creature which Scared the Globe.. 1-13
- 193 COVID-19 update. 138-139 0
- 192 Are countries' precautionary actions against COVID-19 effective? An assessment study of 175 countries worldwide.
- 191 What is Efficacy of Chloroquine/Hydroxychloroquine in Clinical Cure of SARS-CoV 2?; Evidence From an Iranian Population. **2020**, 7,
- 190 Potential Drugs for Treating COVID-19 Infection. **2020**, 7,
- 189 Saudi Heart Rhythm Society Task Force on Management of Potential Arrhythmogenicity Associated with Pharmacotherapy for COVID-19. **2020**, 40, 365-372 0

- 188 Comparative efficacy and safety of current drugs against COVID-19: A systematic review and network meta-analysis.
- 187 Possible role of Unani Pharmacology in COVID-19- a narrative review. **2021**, 36, 391-396 0
- 186 Development of research on COVID-19 by the World Scientific Community in the first half of 2020. **2020**, 5, 1410-1417 1
- 185 COVID-19: Clinical Characteristics and Molecular Levels of Candidate Compounds of Prospective Herbal and Modern Drugs in Indonesia. **2020**, 26, S12-S23 2
- 184 Molecular Docking of Novel 5-O-benzoylpinostrobin Derivatives as SARS-CoV-2 Main Protease Inhibitors. **2020**, 26, S63-S77 2
- 183 A Summary of Coronavirus Disease 2019: What We Should Know?. **2020**, 26, S24-S35
- 182 Covid-19: features of the pathogenesis of the disease and targets for immunotherapeutic effects. **2020**, 20, 75-88
- 181 In-silico identification of natural antiviral drug against SARS-CoV-2 and comparison with potential FDA approved drug targets. **2020**, 3, 1-11
- 180 Gossypetin Derivatives are also Putative Inhibitors of SARS-COV 2: Results of a Computational Study. **2020**, 1, 201-212
- 179 Synthesis and Biological Evaluation of Novel Thionucleosides. **2020**, 24, 1717-1762
- 178 Treatments for COVID-19: emerging drugs against the coronavirus. **2020**, 91, 118-136 7
- 177 Clinical interventions for severe and critical COVID-19: what are the options. **2020**, 12, 2110-2117 2
- 176 What We Learned about COVID-19 So Far? Notes from Underground. **2020**, 21, 185-192 1
- 175 Retrospective analysis of the effect of current clinical medications and clinicopathological factors on viral shedding in COVID-19 patients. **2020**, 13, 68
- 174 Real Clinical Practice and Therapeutic Management Following COVID-19 Crisis in two Hospitals in Iran: A Statistical and Conceptual View. **2020**, 19, 112-121
- 173 How to overcome cardiovascular challenges in COVID-19 patients: a guide for common practice. **2020**, 91, e2020021
- 172 Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review. **2020**, 19, 258-281 1
- 171 Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An approach. **2021**, 153, 132-143

170	Clinical value analysis of IgM and IgG antibodies detected by nucleic acid in patients with COVID-19. 2021 , 13, 7089-7103	
169	Role of environmental factors in transmission of COVID-19. 2022 , 35-72	
168	Insights into the evolutionary and prophylactic analysis of SARS-CoV-2: A review. 2021 , 300, 114375	1
167	Current Updates on Covid-19 Vaccine Research and an Overview of Therapeutic Drug Research. 2021 , 18, 439-457	
166	Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. 2021 , 13,	3
165	Glycyrrhizic acid: Self-assembly and applications in multiphase food systems. 2021 , 43, 107-107	2
164	Computational investigation on natural quinazoline alkaloids as potential inhibitors of the main protease (Mpro) of SARS_CoV_2.	
163	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. 2021 , 10, 1-32	0
162	Mental health burden of patients with diabetes before and after the initial outbreak of COVID-19: predictors of mental health impairment. 2021 , 21, 2068	4
161	Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. 2021 , 71, 39	3
160	Deep Learning Models for Predicting COVID-19 Using Chest X-Ray Images. 2022 , 127-144	2
159	Study of the effects of interferon β 1a on hospitalized patients with COVID-19: SBMU Taskforce on the COVIFERON study. 2021 ,	3
158	A Narrative Review of Existing Options for COVID-19-Specific Treatments. 2021 , 2021, 8554192	
157	Natural Bioactive Molecules: An Alternative Approach to the Treatment and Control of COVID-19. 2021 , 22,	15
156	Thermal Analysis of Protein Stability and Ligand Binding in Complex Media.	
155	SARS-CoV-2 at the human-animal interphase: A review. 2021 , 7, e08496	3
154	Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An approach. 2020 , 153,	1
153	Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review. 2021 , 8, 20499361211063016	0

152	A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.. 2021 , 146, 112550	4
151	Retrospective analysis of the effect of current clinical medications and clinicopathological factors on viral shedding in COVID-19 patients. 2020 , 13, 1-1	
150	Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis - the special case of molnupiravir.. 2022 ,	6
149	Antiviral Drugs and Their Roles in the Treatment of Coronavirus Infection.	0
148	Repurposing Covid-19 Drug : Current Issues. 2022 , 13, 9-16	
147	Use of favipiravir against Covid-19: A Review. 2021 , 5,	
146	Kidneys in SARS-CoV-2 Era; a challenge of multiple faces.. 2022 ,	2
145	Plant-Based Vaccines in Combat against Coronavirus Diseases.. 2022 , 10,	3
144	Computational Approach to Combat COVID-19 Infection: Emerging Tool for Accelerating Drug Research.. 2022 ,	0
143	The Concept Of Repurposing In Covid-19 Infection. 2022 , 03,	
142	SAR and QSAR of COVID-19 Main Protease-Inhibitor Interactions of Recently X-ray Crystalized Complexes.. 2022 , 1-11	1
141	Effects of Covid-19 fear on the attitudes toward Covid-19 vaccination in reproductive women.. 2021 , 1-15	2
140	COVID-19: comprehensive review on mutations and current vaccines. 2021 , 204, 8	5
139	Clinical Features, Diagnostic Evaluation, and Management of COVID-19 Patients.. 2021 , 1353, 1-22	
138	Fármacos de reposicionamiento y fármacos específicos en fase preclínica para la COVID-19. 2021 , 80, 258-268	
137	Pharmacological repurposed agents for COVID-19. 2022 , 441-446	2
136	Domestic violence during COVID-19 pandemic: An issue that needs comprehensive attention and intervention. 2022 , 5, 1	0
135	Brief History, Pathophysiology, Transmission of SARS-CoV-2 Virus, and Recent Advances on Transition Metal Complexes and Nanocomposites as the Potent Antiviral Agents from COVID-19 Perspectives. 2022 , 1-48	

134	Day Level Forecasting of COVID-19 transmission in India using variants of Supervised LSTM models Modeling and Recommendations. 2022 , 15, 0-0		
133	Use of favipiravir against Covid-19: A Review. 2022 , 5,		
132	COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines.. 2022 , 9,		8
131	New In Silico Insights into the Application of (Hydroxy)Chloroquine with Macrolide Antibiotic Co-Crystals against the SARS-CoV-2 Virus. 2022 , 2, 230-243		0
130	Artemisinins in Combating Viral Infections Like SARS-CoV-2, Inflammation and Cancers and Options to Meet Increased Global Demand.. 2022 , 13, 780257		2
129	A Validated Potentiometric Titration Method for Quantitative Determination of Favipiravir from Pharmaceutical Preparation. 2022 , 49-51		2
128	Functional food: complementary to fight against COVID-19.. 2022 , 11, 33		0
127	Analysis of COVID-19 Collective Irrationalities Based on Epidemic Psychology.. 2022 , 13, 825452		
126	A Review on Measures to Rejuvenate Immune System: Natural Mode of Protection Against Coronavirus Infection.. 2022 , 13, 837290		1
125	A Probable Anti-COVID Phytochemical (1,7-Bis-(4-hydroxyphenyl)-1-heptene-3,5-dione) Screened Computationally from the Rhizome of <i>Curcuma longa</i> . 2021 , 7,		
124	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases.. 2021 , 13, 1850-1874		1
123	A computational biology approach for the identification of potential SARS-CoV-2 main protease inhibitors from natural essential oil compounds.. 10, 1313		1
122	Synthetic Coumarin Derivatives as SARS-CoV-2 Major Protease Inhibitors: Design, Synthesis, Bioevaluation and Molecular Docking. 2021 , 6, 13616-13626		1
121	Experience in Using Antiviral Agents for the Treatment of Novel Coronavirus Infection (COVID-19) in Kyrgyzstan. 2021 , 9, 191-199		
120	Drug discovery to treat COVID-19 two years after its outbreak.. <i>Drug Discoveries and Therapeutics</i> , 2021 , 15, 281-288	5	2
119	Multi-Targeted Approaches and Drug Repurposing Reveal Possible SARS-CoV-2 Inhibitors.. 2021 , 10,		0
118	Potential therapeutic effect of Shufeng Jiedu capsule and its major herbs on coronavirus disease 2019 (COVID-19): A review.. <i>Drug Discoveries and Therapeutics</i> , 2022 , 15, 289-299	5	1
117	A Systematic Review on the Therapeutic Relevance of Hydroxychloroquine/Chloroquine in the Management of COVID-19. 2021 , 46, 380-388		0

- 116 COVID-19: The question of genetic diversity and therapeutic intervention approaches.. **2021**, 44, e20200452 ○
- 115 The Significance of Coordinated Research Against SARS-CoV-2. **2022**, 698-713
- 114 Development and Validation of HPLC Method for Quantification of Favipiravir in Tablet. **2022**, 1319-1322 1
- 113 Corona Virus Disease (COVID-19): A past and Present Prospective. **2022**, 45-53
- 112 Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease.. **2022**, 12, 4925 5
- 111 Challenges and implementation of the basic education learning continuity plan in the lens of elementary teachers toward enhanced school-based management operation. **2022**, 11,
- 110 The Arabic version of the fear of covid-19 scale: psychometric properties and relationship to future anxiety in Jordanians. **2022**, 9, 1
- 109 Image_1.jpeg. **2020**,
- 108 Table_1.doc. **2020**,
- 107 Table_1.DOCX. **2020**,
- 106 Data_Sheet_1.PDF. **2020**,
- 105 DataSheet_1.pdf. **2020**,
- 104 Table_1.xlsx. **2020**,
- 103 Table_1.XLSX. **2020**,
- 102 Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form.. **2021**, 20, 1-8 ○
- 101 Potential of propolis against SARS CoV-2 coronavirus infection. **2022**, 159-172
- 100 Overview of Drug Therapy of COVID-19 with Safety and the Potential Clinical Benefits. **2022**, 17,
- 99 SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach with Valproic Acid: A Review. **2022**, 10, 962 ○

- 98 Antimicrobials in COVID-19: strategies for treating a COVID-19 pandemic.. **2022**, ○
- 97 Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation. **2022**, 13, ○
- 96 Therapeutic approaches and vaccination in fighting COVID-19 infections: A review.. **2022**, 27, 101619 ○
- 95 VIRTUAL SCREENING AND MOLECULAR DOCKING ANALYSIS ON THREE SARS-COV-2 DRUG TARGETS BY MULTIPLE COMPUTATIONAL APPROACH. ○
- 94 Revisiting and Updating Cyanorona-20: The Selective SARS-Cov-2 Inhibitor. **2022**, 3, 477-484
- 93 Polytopes of the Highest Dimension in the Theory of Heredity. **2022**, 335-362
- 92 Setomimycin as a potential molecule for COVID-19 target: in silico approach and in vitro validation. ○
- 91 A Single-Centered Cohort Study on Favipiravir Safety and Efficacy in Pediatric Patients with COVID-19. **2022**, In Press,
- 90 Sustainable Solutions for Indoor Pollution Abatement during COVID Phase: A Critical Study on Current Technologies & Challenges. **2022**, 100097 ○
- 89 Bioprospecting for Anti-COVID-19 Interventions From African Medicinal Plants: A Review. **2022**, 17, 1934578X2210969
- 88 The Perils of the Pandemic for the Tourism and Hospitality Industries: Envisaging the Combined Effect of COVID-19 Fear and Job Insecurity on Employees' Job Performance in Pakistan. Volume 15, 1325-1346¹
- 87 Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system. **2022**, 168, 105608 ○
- 86 Therapeutic options in coronavirus treatment. **2022**, 101-135
- 85 Current therapeutic strategies to combat coronavirus disease 2019. **2022**, 137-151
- 84 SARS-CoV-2 vaccine development. **2022**, 227-247 ○
- 83 Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro). **2022**, 8, ○
- 82 Structural, genomic information and computational analysis of emerging coronavirus (SARS-CoV-2). **2022**, 46, 1
- 81 A computational biology approach for the identification of potential SARS-CoV-2 main protease inhibitors from natural essential oil compounds.. 10, 1313 ○

- 80 Therapeutic Repurposing of Antiviral Drugs Available for COVID-19 Therapy: A Mini Review. **2022**, 34, 1993-1996
- 79 Passive Immunotherapeutic Approaches for Treating Covid-19: A Comprehensive Review. **2022**, 11, 52-61 ○
- 78 A FIELD RESEARCH ON THE PERCEPTION OF CORONAFOBIA OF ACCOUNTING PROFESSIONALS.
- 77 Repurposing antiviral phytochemicals from the leaf extracts of *Spondias mombin* (Linn) towards the identification of potential SARSCOV-2 inhibitors. **2022**, 12,
- 76 COVID-19 Mortality and Therapeutics in Nebraska and Southwest Iowa during Early Pandemic. **2022**, 10, 69
- 75 Overview of HCQ and Remdesivir on SARS-CoV-2 (COVID-19). ○
- 74 Chemistry and Biomedical Applications of Cumin and Turmeric: A Review, Challenge and Perspective.
- 73 In silico discovery of multi-targeting inhibitors for the COVID-19 treatment by molecular docking, molecular dynamics simulation studies, and ADMET predictions. 4
- 72 The Dynamic Role of FOXP3+ Tregs and Their Potential Therapeutic Applications During SARS-CoV-2 Infection. 13, 3
- 71 COVID-19 status and its prevention among Indonesian adults. **2022**, 1, ○
- 70 Thermal analysis of protein stability and ligand binding in complex media. **2022**, 715, 179274
- 69 Drugs intervention study in COVID-19 management. **2021**, 36, 87-98
- 68 Long-Term Health Consequences of SARS-CoV-2: Assumptions Based on SARS-CoV-1 and MERS-CoV Infections. **2022**, 12, 1852
- 67 A motley of possible therapies of the COVID-19: reminiscing the origin of the pandemic. 1
- 66 Investigation of Antibiotic Resistome in Hospital Wastewater during the COVID-19 Pandemic: Is the Initial Phase of the Pandemic Contributing to Antimicrobial Resistance?. 1
- 65 Vaccines platforms and COVID-19: what you need to know. **2022**, 8, 1
- 64 Drug repurposing: re-inventing therapies for cancer without re-entering the development pipeline review. **2022**, 34,
- 63 In silico Analysis of ACE2 Receptor to Find Potential Herbal Drugs in COVID-19 Associated Neurological Dysfunctions. **2022**, 17, 1934578X2211185 2

- 62 Review of human interferons and the potential of their use in the complex therapy of a new coronavirus infection COVID-19. **2022**, 14, 38-44
- 61 Nutrition as Personalized Medicine against SARS-CoV-2 Infections: Clinical and Oncological Options with a Specific Female Groups Overview. **2022**, 23, 9136 5
- 60 Nanobionics: From plant empowering to the infectious disease treatment. **2022**, 349, 890-901 0
- 59 Excess Mortality among Physicians and Dentists during COVID-19 in Italy: A Cross-Sectional Study Related to a High-Risk Territory. **2022**, 10, 1684 2
- 58 Polypharmacology in Clinical Applications: Respiratory Polypharmacology. **2022**, 271-299 0
- 57 Duodenal Endoscopic and Histopathologic Findings in a COVID-19 Patient: A Case Report and Literature Review. **2022**, 12, 156-166 0
- 56 Natural drugs for the treatment of severe acute respiratory syndrome coronaviruses infections (SARS-CoV and COVID-19). **2022**, 73-153 0
- 55 Nanocarriers as delivery tool for COVID-19 drugs. **2022**, 293-332 1
- 54 Simple Extractive Spectrophotometric Method for Determination of Favipiravir from Pharmaceutical Formulation. **2022**, 299-302 0
- 53 Hybrid Feature Selection of Breast Cancer Gene Expression Microarray Data Based on Metaheuristic Methods: A Comprehensive Review. **2022**, 14, 1955 1
- 52 COVID-19'dan iyileşenlerin sonrasındaki tedavi rejimlerine göre biventriküler miyokard geriliminin karlılığı. **2022**, 47, 1005-1014 0
- 51 Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity. **2022**, 27, 6127 1
- 50 Neurological changes post-covid-19 infection. **2022**, 10, 336-350 0
- 49 DPPH and Nitric Oxide Free Radical Scavenging Potential of Phenyl Quinoline Derivatives and Their Transition Metal Complexes. **2022**, 134058 0
- 48 Efficacy of drug regimen with and without oseltamivir in hospitalized patients with COVID-19: A retrospective study. **2022**, 0 0
- 47 A Study on COVID-19, Its Origin, Phenomenon, Variants, and IoT-Based Framework to Detect the Presence of Coronavirus. **2023**, 1-13 0
- 46 Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. **2022**, 16, 175346662211327 0
- 45 Self-assembled Glycyrrhetic Acid Derivatives for Functional Applications:A Review. 0

44	Scientific production on medicinal plants and their efficacy against Covid-19: A review and scientometric analysis based on VOSviewer. 2022,	0
43	A Guide to COVID-19 Antiviral Therapeutics: A Summary and Perspective of the Antiviral Weapons Against SARS-CoV-2 Infection.	1
42	Factors Associated with Self-Medication during the COVID-19 Pandemic: A Cross-Sectional Study in Pakistan. 2022, 7, 330	2
41	Highly pathogenic coronaviruses and the kidney. 2022, 156, 113807	0
40	Quinone and SARS-CoV-2. 2023, 47-81	0
39	COVID-19. 2023, 173-273	0
38	Insight into the role of clathrin-mediated endocytosis inhibitors in SARS-CoV-2 infection.	0
37	COVID-19 Fear and Anxiety among Patients with Chronic Heart Failure: A Cross Sectional Study. 2022, 11, 6586	0
36	Hybrid Multi-Criterion Decision-Making Method to Prioritize the Post-COVID-19 Syndrome Follow Up Care. 2022, 14, 1-22	0
35	Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. 13,	0
34	RNA G-quadruplex forming regions from SARS-2, SARS-1 and MERS coronaviruses. 10,	0
33	Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19-Induced ARDS Patients: A Case Report. 2022, 58, 1698	0
32	In vitro screening of anti-viral and virucidal effects against SARS-CoV-2 by Hypericum perforatum and Echinacea. 2022, 12,	1
31	Causal Model Analysis of the Effect of Policy Formalism, COVID-19 Fear, Social Support and Work Stress on Construction Workers' Anxiety during the Epidemic. 2023, 13, 10	1
30	Identification of multi-targeting natural antiviral peptides to impede SARS-CoV-2 infection.	0
29	Comparative Analysis of the Efficiency of Medicinal Plants for the Treatment and Prevention of COVID-19. 2022, 2022, 1-14	0
28	Computational Deep Learning Models for Detection of COVID-19 Using Chest X-Ray Images. 2023, 291-306	0
27	The Potential of Stilbene Compounds to Inhibit Mpro Protease as a Natural Treatment Strategy for Coronavirus Disease-2019. 2023, 45, 12-32	0

- 26 Pharmacological Effects and Clinical Prospects of Cepharanthine. **2022**, 27, 8933 ○
- 25 Computational Studies of Auto-Active van der Waals Interaction Molecules on Ultra-Thin Black-Phosphorus Film. **2023**, 28, 681 1
- 24 Hydroxychloroquine for treatment of non-hospitalized adults with COVID -19: A meta-analysis of individual participant data of randomized trials. ○
- 23 Electrochemical sensor based on a ZnO-doped graphitized carbon for the electrocatalytic detection of the antibiotic hydroxychloroquine. Application: tap water and human urine. ○
- 22 Causal Model Analysis of the Effect of Formalism, Fear of Infection, COVID-19 Stress on Firefighters' Post-Traumatic Stress Syndrome and Insomnia. **2023**, 20, 1097 ○
- 21 New Analytical Methods for the Determination of New Anti-Viral Drug Favipiravir: A Potential Therapeutic Drug Against Covid-19 Virus, in Bulk and Dosage Forms. ○
- 20 COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte. **2023**, 16, 233-249 ○
- 19 Major royal jelly proteins elicited suppression of SARS-CoV-2 entry and replication with halting lung injury. **2023**, 228, 715-731 ○
- 18 Favipiravir's tautomeric and Complexation Properties in Solution. **2023**, 16, 45 ○
- 17 Applications of multiomics data in COVID-19. **2023**, 351-365 ○
- 16 Therapeutic Repurposing Approach: New Opportunity for Developing Drugs Against COVID-19. **2023**, 543-568 ○
- 15 Immunotherapeutic approaches in the treatment of COVID-19. **2020**, 15, 19-26 ○
- 14 Nanomedicine for drug resistant pathogens and COVID-19 using mushroom nanocomposite inspired with bacteriocin [A review. **2023**, 152, 110682 ○
- 13 Remdesivir and Breastfeeding [A Case Report. **2023**, 14, 22-25 ○
- 12 Therapeutically important bioactive compounds of the genus Polygonum L. and their possible interventions in clinical medicine. **2023**, 75, 301-327 ○
- 11 Relation of COVID-19 with liver diseases and their impact on healthcare systems: The Portuguese case. 29, 1109-1122 ○
- 10 1,3,4-Oxadiazole derivatives as potential antifungal agents: Synthesis, characterization, Ct-DNA binding, molecular docking, and TD-DFT studies. ○
- 9 Comparative Study of Molecular Docking, Structural, Electronic, and Fukui Function Studies on Favipiravir and its Newly Designed Derivatives (Potential Inhibitors) for COVID-19 Protease. **2023**, 407, ○

- 8 Application of Virtual Screening and Molecular Modeling Technologies to Identify Potential SARS-CoV-2 Main Protease Inhibitors. **2023**, 18, 15-32
- 7 Intelligent prognostic system for pediatric pneumonia based on sustainable IoHT.
- 6 Platinum-Nucleos(t)ide Compounds as Possible Antimetabolites for Antitumor/Antiviral Therapy: Properties and Perspectives. **2023**, 15, 941
- 5 Evaluation of [¹⁸F]Favipiravir in Rodents and Nonhuman Primates (NHP) with Positron Emission Tomography. **2023**, 16, 524
- 4 Synergy of Small Antiviral Molecules on a Black-Phosphorus Nanocarrier: Machine Learning and Quantum Chemical Simulation Insights. **2023**, 28, 3521
- 3 Predictive analysis, diagnosis of COVID-19 through computational screening and validation with spectro photometrical approach.
- 2 Targeting the vital non-structural proteins (NSP12, NSP7, NSP8 and NSP3) from SARS-CoV-2 and inhibition of RNA polymerase by natural bioactive compound naringenin as a promising drug candidate against COVID-19. **2023**, 1287, 135642
- 1 Do executive functions buffer against COVID-19 stress?.